Apogee Therapeutics (NasdaqGM:APGE) Update / briefing Transcript

Apogee Therapeutics Conference Call Summary Company Overview - Company: Apogee Therapeutics (NasdaqGM:APGE) - Focus: Development of treatments for atopic dermatitis and type two inflammation Industry Context - Market Size: Atopic dermatitis is projected to become the largest I&I market, potentially exceeding $50 billion [4][32] - Current Treatments: Limited options exist, with even modestly differentiated products achieving blockbuster status [4] Key Points from the Call Clinical Development and Results - Drug: Zumilokibart (Zumi) - Study: APECS Part A 52-week maintenance results - Efficacy: - 75% maintenance of EASI-75 response with 3-month dosing - 85% maintenance of EASI-75 response with 6-month dosing - 86% maintenance of IGA 0/1 response with 3-month dosing - 78% maintenance of IGA 0/1 response with 6-month dosing [5][12] - Deepening Responses: Observed across all endpoints tested, contrasting with Dupixent, which plateaued after week 16 [6][15] - Safety Profile: Well-tolerated with adverse events consistent with the IL-13 class, including a 20.2% rate of non-infective conjunctivitis [11][25] Market Opportunity - Unmet Need: Significant quality-of-life impact for patients with atopic dermatitis, including sleep loss and mood disorders [21][22] - Dosing Advantage: Zumi offers a reduced injection burden (2-4 times per year) compared to standard care (26 times per year) [31][32] - Potential Launch: Planned for 2029, with expectations of becoming a first-line treatment option [29][32] Future Directions - Phase III Trials: On track to initiate in the second half of the year, with part B results expected in Q2 2026 [29][33] - Expansion Potential: Zumi's application may extend to asthma and eosinophilic esophagitis, with positive phase I-B asthma data already disclosed [29] Competitive Landscape - Comparison with Other Treatments: Zumi's efficacy and safety profile position it favorably against existing treatments like Dupixent and JAK inhibitors [72] - Market Penetration: Atopic dermatitis remains underpenetrated, with new entrants quickly achieving blockbuster status [32] Conclusion - Strategic Vision: Apogee aims to establish itself as a leader in the I&I market by delivering innovative treatments that address significant unmet needs in atopic dermatitis [32][34]